India, March 24 -- The Government of India has issued a release:
In order to ensure ethical pharmaceutical practices in the supply chain of Weight Loss Drug (GLP-1), the Drugs Controller of India has intensified its regulatory surveillance against the drug's unauthorized sale and promotion.
With the recent introduction of multiple generic variants of GLP-1-based weight loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks.
Taking cognizance of the situation, India's Drugs Controller, in collaboration w...